Find Events Find People Find Jobs Find Sites Find Help Index


January 22, 2002

Enzyme discovery could open doors for new drugs

By Holly Korschun



Scientists from the School of Medicine and the University of Pavia in Italy have determined for the first time the three-dimensional structure of monoamine oxidase B (MAO-B)—an enzyme important in several major disease processes; particularly age-related neurological disorders.

Understanding the detailed structure of the enzyme should provide a framework for designing new neuroprotective drugs. The research is published in the January 2002 edition of Nature Structural Biology.

Monoamine oxidases (MAO-B and MAO-A) are well-known targets for antidepressant drugs and for drugs used to treat neurological disorders and diseases of aging, such as Parkinson’s and Alzheimer’s diseases. MAO-A and MAO-B are attached to the outer membrane of the mitochondria—the energy powerhouses of cells—and oxidize amine neurotransmitters such as dopamine and serotonin.

Through their model of the enzyme’s structure, the Emory and Pavia scientists revealed the architecture of the enzyme’s active site, which is responsible for its catalytic properties. They also described sites on the enzyme responsible for its binding to the membrane.

Pharmacologists have designed a number of drugs, both reversible and irreversible, that inhibit MAO-B and are used to treat neurological disorders. For example, the MAO-B inhibitor deprenyl is administered to increase the effectiveness of L-dopa therapy in the treatment of Parkinson’s disease and to provide neuroprotective effects in patients with pre-Parkinson’s syndrome.

Recent studies have demonstrated that MAO-B is inhibited by compounds present in tobacco smoke, which may contribute to the addictive properties of tobacco use. Scientific and clinical interest in these enzymes has been ongoing for more that 40 years and has resulted in more than 15,000 papers published on their biological properties.

“Although scientists already have made considerable progress in the development of MAO-B inhibitors to treat neurodegenerative and psychiatric disorders, we are very optimistic that our new knowledge about the three-dimensional structure of the enzyme will facilitate additional improvements in drug design, which will lead to increased specificity and fewer side effects,” said Dale Edmondson, professor of biochemistry and co-principal investigator of the project.

MAO-B has been shown to be elevated more than threefold in the brain tissue of elderly individuals. Recent studies have shown that elevated levels of MAO-B in neurons and kidney cells can lead to cell death (apoptosis). Clinical trials currently are under way in several centers to target increased levels of MAO-B that have been identified in astrocytes (a type of brain cell) in Alzheimer’s patients.

“The structural insights will provide us with a new framework to explore the catalytic mechanism of the enzyme, to understand the differences between the A and B forms, and to design specific new inhibitors to treat and prevent age-related disorders,” Edmondson said. “It also will help us understand the role of these enzymes in the clearance of amine-containing drugs, either in development or in clinical use for the treatment of other disorders.”

“This finding may well result in the development of novel treatments for depression—a major public health problem,” said Charles Nemeroff, Reunette W. Harris professor of psychiatry and behavioral sciences. “MAO inhibitors are excellent antidepressants but have an unfavorable side-effect profile. This discovery should allow for the synthesis of novel MAO inhibitors with great selectivity and few side effects.”

Other researchers in the study included co-principal investigator Andrea Mattevi, from the University of Pavia’s genetics and microbiology department, and postdoctorals Claudia Binda, Paige Newton-Vinson and Frantisek Hubalek.




Back to Emory Report January 22, 2002

Emory University, Copyright 2002